@article{Xiao2026, 
author = {Chuangmeng Xiao and Xinyi Xie and Liqi Lv and Jiangling Duan and Xiaokun Zhang and Yue Li and Yanjun Wang and Hongzhuan Chen and Qingyan Sun and Jinmei Jin and Xin Luan and Weidong Zhang},
title = {A santonin derivative, QX-6, alleviates ulcerative colitis by suppressing macrophage oxidative stress and inflammatory responses via modulation of ferroptosis-related signaling},
year = {2026},
journal = {Chinese Journal of Natural Medicines},
volume = {24},
number = {12},
pages = {1499-1508},
keywords = {Ulcerative colitis, Ferroptosis, Reactive oxygen species, Regulatory mechanism},
url = {https://www.sciopen.com/article/10.1016/S1875-5364(26)61236-8},
doi = {10.1016/S1875-5364(26)61236-8},
abstract = {Ulcerative colitis (UC) is an inflammatory bowel disease primarily affecting the colon and rectum. Current therapies, including corticosteroids, immunosuppressants, biologics, and 5-aminosalicylates, remain limited by suboptimal efficacy, adverse effects, and drug resistance, highlighting the need for safer and more effective therapeutic agents. In the present study, we identified QX-6 as a novel small-molecule compound with potent anti-inflammatory activity. In lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages and bone marrow-derived macrophages (BMDMs), QX-6 markedly reduced the expression of pro-inflammatory cytokines and reactive oxygen species (ROS) production. Multi-omics analyses further revealed significant enrichment of ferroptosis related pathways following QX-6 treatment. Consistently, QX-6 regulated the expression of ferroptosis-related proteins, including NRF2, HMOX1, GCLM, GPX4, FTL, and SLC40A1, while reducing ROS accumulation and lipid peroxidation and ameliorating ferroptosis-associated mitochondrial alterations in macrophages. Moreover, pharmacological induction of ferroptosis partially reversed the inhibitory effects of QX-6 on inflammatory cytokine expression and lipid peroxidation, further supporting the involvement of ferroptosis-related signaling in its anti-inflammatory activity. In vivo, QX-6 treatment significantly alleviated colon shortening in experimental models of UC, with the 120 mg·kg−1 dose showing the strongest protective effect, surpassing that of the positive control drug 5-aminosalicylic acid. Overall, these findings demonstrate that QX-6 exerts significant anti-inflammatory effects both in vitro and in vivo, and suggest that it may serve as a promising therapeutic candidate for UC.}
}